Vida Ventures

vidaventures.com

VCMatch tracks Vida Ventures as an investor focused on Biotech, Pharma, and Medtech companies, Pre-Seed and Seed rounds, United States markets, and $1.8b check sizes. Upload your deck to compare your startup against the full private matching profile.

Check Size

$1.8b

Stages

Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage

Focus Areas

Biotech, Pharma, Medtech

Geography

United States

Investment Thesis

Vida Ventures invests to “bring science to life” by advancing transformative biomedical innovations with the explicit goal of making a meaningful difference for patients. The firm is founder/operator-led and frames investing as building and funding breakthroughs in biomedicine, combining deep scientific and clinical expertise with operational experience to support companies “along the continuum of discovery and development.” Vida emphasizes a pragmatic, flexible model—able to create and back companies at any stage and across therapeutic areas—aimed at translating bold science into medicines while keeping patients front and center.

Is Vida Ventures right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

Vida Ventures is most relevant for founders raising Pre-Seed, Seed, and Series A rounds in Biotech, Pharma, Medtech, and AI/ML, especially across United States, with public check-size signals around $1.8b.

Focus statement

Vida’s stated core focus is therapeutics: “Our core area of focus lies in therapeutics,” and the firm targets transformative biomedical innovations across stages and therapeutic areas, supporting company creation through later development.

Value Add

Founding and leadership team comprised of scientists, physicians, entrepreneurs and experienced operators (e.g., Arie Belldegrun, founders of Kite and Allogene) – strong company-building pedigree.
Operational/investor-operator model: ability to ‘build and back companies regardless of stage’ and support companies ‘along the continuum of discovery and development.’
Deep scientific and clinical bench: extensive Scientific Advisory Board and senior advisors with proven drug-development track records (e.g., leaders from Kite, Gilead, Genentech, major academic chairs).
Patient-centric, mission-driven orientation: explicit emphasis to “keep [patients] front and center” and to “do well by doing good for others.”
Flexible capital and scope: bicoastal presence and ~$1.8 billion under management enabling investments across stage and therapeutic areas.
Programs to source and develop talent/technology (e.g., Fellowship program and in-house specialists across BD, ops, finance and communications).